Conatus Pharmaceuticals, a biotech focused on the development of novel medicines to treat liver disease, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $55 million by offering 5 million shares at a price range of $10 to $12. At the midpoint of the proposed range, Conatus Pharmaceuticals would command a fully diluted market value of $160 million.
Conatus Pharmaceuticals, which was founded in 2005, plans to list on the NASDAQ under the symbol CNAT. Conatus Pharmaceuticals initially filed confidentially on May 10, 2013. Stifel and Piper Jaffray are the joint bookrunners on the deal.
